Clinical trials: Transthyretin Amyloidosis
Amyloidosis, Hereditary, Amyloidosis Cardiac
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein.
- Conditions
- Amyloidosis, Hereditary, Amyloidosis Cardiac, Amyloidosis, Familial, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Trial name
- NCT05489549
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Texas Southwestern Medical Center
Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis
Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium.
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis, Cardiomyopathies, Wild-Type Transthyretin Cardiac Amyloidosis
- Trial name
- LICA2025 (NCT07766135)
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Messina
Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
- Trial name
- NCT05040373
- Where
- 7 sites in United States, France and 5 more
- Volunteers
- 10 people
- Sponsor
- Alnylam Pharmaceuticals
Transthyretin (TTR) Amyloid Cardiomyopathy
Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study
The objective of this study is to determine the association of clinically prescribed, on-label, TTR stabilizing therapy (e.g. tafamidis or acoramidis) with levels of circulating transthyretin amyloid aggregates (TAAs, a surrogate…
- Trial name
- NCT07196839
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
ATTR-PN
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
This is a Phase 3, open-label study designed to obtain additional long-term safety and efficacy data for oral tafamidis (20 mg soft gelatin capsule) administered once daily (QD).
- Trial name
- NCT00925002
- Testing
- Tafamidis
- Where
- 9 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- Pfizer
TTR-mediated Amyloidosis, Amyloidosis, Hereditary
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies
- Trial name
- NCT02939820
- Testing
- patisiran (ALN-TTR02)
- Sponsor
- Alnylam Pharmaceuticals
Light Chain Cardiac Amyloidosis
CAR-NK Therapy for Cardiac Amyloidosis
Relapsed/refractory (R/R) light chain cardiac amyloidosis is associated with a poor prognosis, and cellular immunotherapy constitutes a crucial therapeutic modality for these patients.
- Trial name
- NCT07504289
- Testing
- CAR-NK
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Amyloid Cardiomyopathy
Amyloidosis TTR Flow Reserve Evaluation
Anginal symptoms and signs of ischemia have been reported in some patients with cardiac amyloidosis (TTR) without obstructive epicardial coronary artery disease (CAD).
- Trial name
- AMYTRE (NCT05103943)
- Testing
- SPECT MPI
- Where
- 4 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Transthyretin Mediated Amyloidosis (ATTR)
Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT01148953
- Testing
- ALN-TTR01, Sterile Normal Saline (0.9% NaCl)
- Where
- 4 sites in France, Portugal and 2 more
- Volunteers
- 32 people
- Sponsor
- Alnylam Pharmaceuticals
Transthyretin Familial Amyloid Polyneuropathy
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
- Trial name
- NCT01435655
- Testing
- tafamidis
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Transthyretin Amyloidosis, Carpal Tunnel Syndrome
Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
This study will determine the prevalence of transthyretin amyloidosis in pathology of the transverse carpal ligament and cardiac involvement using natriuretic peptides, electrocardiography and echocardiography in patients…
- Trial name
- PRATHYC (NCT04611204)
- Testing
- Descriptive cohort
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Toulouse
Amyloid Cardiomyopathy, Block, AV
Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation
The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block…
- Trial name
- ATTRAB (NCT05699044)
- Testing
- Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)
- Where
- Denmark
- Volunteers
- 170 people
- Sponsor
- Steen Hvitfeldt Poulsen
Amyloidosis, AL Amyloidosis
BE.Amycon Biobank & Data Registry UZ Leuven
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database…
- Conditions
- Amyloidosis, AL Amyloidosis, Amyloidosis Cardiac
- Trial name
- NCT07172243
- Where
- 2 sites in Belgium
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
- Trial name
- NCT04153149
- Testing
- Vutrisiran, Sterile Normal Saline (0.9% NaCl)
- Where
- 121 sites in United States, Argentina and 31 more
- Volunteers
- 655 people
- Sponsor
- Alnylam Pharmaceuticals
Heart Failure
Heart Failure: Don't Forget the Role of Amyloidosis
Heart failure is defined as the inability of the heart to provide sufficient output to meet the needs of the body. It can occur in the course of a myocardial infarction, angina pectoris, hypertension, etc.
- Trial name
- TEAM-HF (NCT05501847)
- Testing
- Patient with no ventricular hypertrophy
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 446 people
- Sponsor
- University Hospital Center of Martinique
Familial Amyloid Polyneuropathy, Familial Amyloidosis
The Effect of Diflunisal on Familial Amyloidosis
The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy.
- Trial name
- NCT00294671
- Testing
- diflunisal
- Where
- 8 sites in United States, Italy and 3 more
- Volunteers
- 130 people
- Sponsor
- Boston University
Cardiac Amyloidosis, Pacemaker
Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis
In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more…
- Trial name
- PACE-ATTR (NCT07413081)
- Testing
- Increasing the pacemaker lower rate, Standard setting
- Where
- 9 sites in Denmark, Sweden
- Volunteers
- 34 people
- Sponsor
- Region Skane
Transthyretin Amyloid Cardiomyopathy
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid.
- Trial name
- ACO-SWITCH (NCT07298044)
- Testing
- Acoramidis
- Where
- 26 sites in Austria, Belgium and 3 more
- Volunteers
- 50 people
- Sponsor
- Bayer
Cardiac TTR Amyloidosis
Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease
Cardiac amyloidosis is a multi-organ syndrome, which usually presents as restrictive cardiomyopathy (RCM). Transthyretin (TTR) amyloidosis (or ATTR) is a subtype of amyloidosis which frequently involves heart.
- Trial name
- NCT03098901
- Testing
- Tc99m-labeled pyrophosphate scan
- Volunteers
- 100 people
- Sponsor
- Kaplan Medical Center
TTR-mediated Amyloidosis
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT01617967
- Testing
- Patisiran
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 29 people
- Sponsor
- Alnylam Pharmaceuticals